nitro (3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dinitrooxyhept-6-enoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: nitro (3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dinitrooxyhept-6-enoate
• 化学式: C26H31FN4O11
• 分子量: 594.5
• InChiKey: TZPANPHRLYRSAE-WOJBJXKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  42
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  204
• 氢给体数：
  0
• 氢受体数：
  13

文献信息

• Nitric oxide donating derivatives for the treatment of cardiovascular disorders
  申请人：Tucker Joseph

  公开号：US20050080024A1

  公开（公告）日：2005-04-14

  Compounds comprising nitric oxide derivatives of stilbenes, polyphenols and flavonoids and methods of their use are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.

  本发明提供了由stilbenes、多酚和类黄酮的亚硝酸盐衍生物组成的化合物，以及它们的使用方法，用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者。
• Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
  申请人：Tucker Joseph

  公开号：US20050080021A1

  公开（公告）日：2005-04-14

  Compounds and methods are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.

  提供了用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者的化合物和方法。
• NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS
  申请人：RESVERLOGIX CORP.

  公开号：EP1670484A1

  公开（公告）日：2006-06-21
• Treatment of diseases associated with the egr-1 enhancer element
  申请人：Wong Norman

  公开号：US20070099826A1

  公开（公告）日：2007-05-03

  Compounds and methods are provided for treating patients suffering from health condition associated with an expression state of a gene such as fertility disorders, cancer, proliferative diseases, vascular diseases, wounds requiring therapeutic intervention, inflammation, and pulmonary disorders by administering to said patient a compound capable of modulating egr-1 and/or an egr-1 response element consensus sequence thereby altering the expression state of said gene. Also described are new methods for screening compounds to identify effectors of egr-1 and/or egr-1 consensus sequence elements and methods for treating patients by administering such effectors to modulate egr-1 and/or egr-1 consensus sequences to thereby modify expression of genes associated therewith to in turn treat diseases or other physiological conditions associated with such gene expression.
• [EN] NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS<br/>[FR] DERIVES DONATEURS D'OXYDE NITRIQUE PERMETTANT DE TRAITER LES TROUBLES CARDIO-VASCULAIRES
  申请人：RESVERLOGIX CORP

  公开号：WO2005032559A1

  公开（公告）日：2005-04-14

  Compounds for inducing the expression of ApoA1, comprising a donatable nitric oxide moiety and a free-radical scavenging moiety. Preferably, nitric oxide derivatives of stilbenes, polyphenols, flavonoids and isoflavonoids and methods of their use are provided for treating patients suffering from diseases including hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.